GlassScriptPhysician profile
Dina R Block
NPI 1497996318
$1,745.67
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $27.38 · 2021: $735 · 2022: $684 · 2023: $73.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $73.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $73.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $588.37 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $299.51 | 2019-2022 | |
| Insulet Corporation | $244.95 | 2019-2021 | |
| Abbvie INC. | $92.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.89 | 2019-2022 | |
| Abbott Laboratories | $73.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $45.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $45.57 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.37 | 2022 | |
| Sanofi-Aventis U.S. LLC | $40.47 | 2021-2022 | |
| Mannkind Corporation | $38.38 | 2019 | |
| Becton, Dickinson and Company | $38.21 | 2021 | |
| Zealand Pharma US, INC. | $21.60 | 2022 | |
| Tandem Diabetes Care, INC. | $18.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.